Dr. Yvonne Greenstreet, an 18-year veteran at GlaxoSmithKline (NYSE: GSK), is joining rival Pfizer in a drug development role.

Greenstreet most recently served as senior vice president and chief of strategy for research and development.

At Pfizer, her title is senior vice president and head of medicines development for Pfizer’s Specialty Care Business Unit.

“Yvonne has a strong track record of leadership and outstanding results during her career in the biopharmaceutical industry,” said Geno Germano, president and general manager of Pfizer’s Specialty Care Business Unit, in a statement. “Her experience in delivering medicines in challenging markets is noteworthy, and she will play an important role in advancing Specialty Care’s commitment to the eradication, remission and relief of serious diseases.”

GSK maintains its U.S. headquarters in RTP.

Read the full announcement from Pfizer here.

Get the latest news alerts: Follow WRAL Tech Wire at Twitter.